DK2473636T3 - Type 1-interferondiagnostik - Google Patents

Type 1-interferondiagnostik Download PDF

Info

Publication number
DK2473636T3
DK2473636T3 DK10814513.7T DK10814513T DK2473636T3 DK 2473636 T3 DK2473636 T3 DK 2473636T3 DK 10814513 T DK10814513 T DK 10814513T DK 2473636 T3 DK2473636 T3 DK 2473636T3
Authority
DK
Denmark
Prior art keywords
ifna
ifn
rsad2
ifi44l
ifi44
Prior art date
Application number
DK10814513.7T
Other languages
English (en)
Inventor
Wei Zhu
Chris Morehouse
Barbara White
Bahija Jallal
Yihong Yao
Brandon Higgs
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Application granted granted Critical
Publication of DK2473636T3 publication Critical patent/DK2473636T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Fremgangsmåde til identificering af en person, der er egnet til behandling af lupus med et anti-interferon-alfa-antistof eller et anti-interferon-alfa-receptor-antistof, der modulerer type 1-interferonaktivitet, som omfatter påvisning af et forhøjet niveau af mRNA af en gruppe af gener, der består af IFI27, IFI44, IFI44L og RSAD2, i en prøve fra personen, hvor en gennemsnitlig gange ændring i mRNA'et af gruppen af gener på mindst 4 gange indikerer, at en person er egnet til behandling af lupus med antistoffet, hvor stigningen er i forhold til a) niveauet i en prøve fra et væv eller en person, der ikke har sygdommen, eller b) ekspressionen af et eller flere kontrolgener.
2. Fremgangsmåde ifølge krav 1, hvor anti-interferon- antistoffet er sifalimumab.
3. Fremgangsmåde ifølge krav 1, hvor anti-interferon- antistoffet ikke er sifalimumab.
4. Fremgangsmåde ifølge krav 1, hvor påvisning af mRNA af IFI27, IFI44, IFI44L og RSAD2 omfatter a) isolering af RNA fra en prøve opnået fra personen; b) syntetisering af cDNA fra RNA'et; c) hybridisering af cDNA'et med oligonukleotider, der hybridiserer til nukleinsyresekvenser ifølge SEQ ID NO: 25 til 28 og 32; og d) amplificering af cDNA'et og påvisning af de amplificerede produkter.
5. Fremgangsmåde ifølge krav 4, hvor oligonukleotiderne er udvalgt blandt oligonukleotider med sekvenserne ifølge SEQ ID NO: 13 til 24.
6. Anti-interferon-alfa-antistof eller anti-interferon-alfa-receptor-antistof, der modulerer type 1-interferonaktivitet, til anvendelse til behandling af lupus hos en egnet person, hvor personen, der er egnet til behandling, identificeres ved påvisning af et forhøjet niveau af mRNA af en gruppe af gener, der består af IFI27, IFI44, IFI44L og RSAD2, i en prøve fra personen, hvor en gennemsnitlig gange ændring i mRNA'et af gruppen af gener på mindst 4 gange indikerer, at en person er egnet til behandling af lupus, hvor stigningen er i forhold til a) niveauet i en prøve fra et væv eller en person, der ikke har sygdommen, eller b) ekspressionen af et eller flere kontrolgener.
7. Antistof til anvendelse ifølge krav 6, hvor anti- interferon-antistoffet er sifalimumab.
8. Antistof til anvendelse ifølge krav 6, hvor anti- interferon-antistoffet ikke er sifalimumab.
9. Antistof til anvendelse ifølge krav 6, hvor påvisning af mRNA'et af IFI27, IFI44, IFI44L og RSAD2 omfatter a) isolering af RNA fra en prøve opnået fra personen; b) syntetisering af cDNA fra RNA'et; c) hybridisering af cDNA'et med oligonukleotider, der hybridiserer til nukleinsyresekvenser ifølge SEQ ID NO; 25 til 28 og 32; og d) amplificering af cDNA'et og påvisning af de amplificerede produkter.
10. Antistof til anvendelse ifølge krav 9, hvor oligonukleotiderne er udvalgt blandt oligonukleotider med sekvenserne ifølge SEQ ID NO: 13 til 24.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5 eller antistof til anvendelse ifølge et hvilket som helst af kravene 6 til 10, hvor det forhøjede niveau af mRNA er i forhold til puljede prøver fra raske personer.
12. Fremgangsmåde ifølge et hvilket som helst af kravene lb) eller 2 til 5 eller 11 i den udstrækning kravene 2 til 5 og 11 henviser tilbage til krav lb) eller antistof til anvendelse ifølge et hvilket som helst af kravene 6b) eller 7 til 11 i den udstrækning krav 7 til 11 henviser tilbage til krav 6b) , hvor kontrolgenerne er udvalgt blandt ACTB, GAPDH og 18S-rRNA.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, 11 eller 12 eller antistof til anvendelse ifølge et hvilket som helst af kravene 6 til 12, hvor prøven er fuldblod eller serum.
14. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5 eller 11 til 13 eller antistof til anvendelse ifølge et hvilket som helst af kravene 6 til 13, hvor personen har brug for behandling af systemisk lupus erythematosus.
DK10814513.7T 2009-09-03 2010-09-02 Type 1-interferondiagnostik DK2473636T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23963009P 2009-09-03 2009-09-03
PCT/US2010/047721 WO2011028933A1 (en) 2009-09-03 2010-09-02 Type 1 interferon diagnostic

Publications (1)

Publication Number Publication Date
DK2473636T3 true DK2473636T3 (da) 2017-02-06

Family

ID=43649646

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10814513.7T DK2473636T3 (da) 2009-09-03 2010-09-02 Type 1-interferondiagnostik

Country Status (23)

Country Link
US (3) US20120251546A1 (da)
EP (1) EP2473636B1 (da)
JP (2) JP5727484B2 (da)
KR (1) KR20120101340A (da)
CN (1) CN102753704A (da)
AU (1) AU2010289383B2 (da)
BR (1) BR112012004781A2 (da)
CA (1) CA2772921A1 (da)
CY (1) CY1118566T1 (da)
DK (1) DK2473636T3 (da)
ES (1) ES2613055T3 (da)
HR (1) HRP20170091T1 (da)
HU (1) HUE032917T2 (da)
LT (1) LT2473636T (da)
ME (1) ME02599B (da)
MX (1) MX2012002640A (da)
PL (1) PL2473636T3 (da)
PT (1) PT2473636T (da)
RS (1) RS55641B1 (da)
RU (1) RU2012112802A (da)
SI (1) SI2473636T1 (da)
SM (2) SMT201700063T1 (da)
WO (1) WO2011028933A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488632A1 (en) * 2002-06-11 2003-12-18 Idaho Research Foundation Type i interferon-inducible proteins to detect viral infection
EP2712930A3 (en) * 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
CA2686861A1 (en) * 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
KR20140048877A (ko) * 2011-04-26 2014-04-24 제넨테크, 인크. 자가면역 질환의 치료를 위한 조성물 및 방법
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR102320059B1 (ko) 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN105316404B (zh) * 2015-02-27 2017-02-22 中南大学湘雅二医院 系统性红斑狼疮生物标志物及其诊断试剂盒
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
CN105567861B (zh) * 2016-03-16 2018-12-14 宫蕊 Ifi27作为冠心病诊断标志物的用途
SG11202108679PA (en) * 2019-02-15 2021-09-29 Astrazeneca Ab Type i interferon-mediated disorders
EP4494712A3 (en) 2019-11-11 2025-03-26 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4157873A2 (en) 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
JP2023544351A (ja) * 2020-10-02 2023-10-23 セルジーン コーポレーション 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022106460A2 (en) 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CA3216395A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CA3216390A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of cutaneous lupus erythematous
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
MX2023013015A (es) * 2021-05-04 2023-11-15 Viela Bio Inc Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
IL308128A (en) 2021-05-12 2023-12-01 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
KR20240038773A (ko) 2021-07-27 2024-03-25 아스트라제네카 아베 루푸스의 치료
JP2024536320A (ja) 2021-10-04 2024-10-04 アストラゼネカ・アクチエボラーグ ループスの処置
IL319505A (en) 2022-09-14 2025-05-01 Viatris Asia Pacific Pte Ltd S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon
CN120344259A (zh) 2022-10-13 2025-07-18 阿斯利康(瑞典)有限公司 狼疮的治疗
AU2024277546A1 (en) 2023-05-19 2026-01-15 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US7247425B2 (en) * 1998-01-30 2007-07-24 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US7749695B2 (en) * 2003-03-03 2010-07-06 Alexander Abbas PRO polypeptides for diagnosis of systemic lupus erythematosis
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
JP2007525458A (ja) 2003-04-23 2007-09-06 メダレックス インコーポレイテッド インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
JP2007527247A (ja) * 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
DK2327792T3 (da) * 2005-08-05 2014-01-13 Genentech Inc Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
EP2052088A2 (en) * 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
EP2712930A3 (en) * 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
CA2686861A1 (en) * 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
KR20110005783A (ko) * 2008-02-08 2011-01-19 메디뮨 엘엘씨 질환 마커 및 그의 용도
US20110117563A1 (en) * 2008-04-21 2011-05-19 Witold Filipowicz Antiviral therapy
WO2009149319A2 (en) * 2008-06-05 2009-12-10 Wyeth Gene expression profiles associated with asthma exacerbation attacks

Also Published As

Publication number Publication date
US20150191788A1 (en) 2015-07-09
SI2473636T1 (sl) 2017-04-26
HRP20170091T1 (hr) 2017-03-24
CN102753704A (zh) 2012-10-24
EP2473636A1 (en) 2012-07-11
PT2473636T (pt) 2017-02-06
US20120251546A1 (en) 2012-10-04
PL2473636T3 (pl) 2017-05-31
JP2015147788A (ja) 2015-08-20
WO2011028933A1 (en) 2011-03-10
RS55641B1 (sr) 2017-06-30
MX2012002640A (es) 2012-06-25
KR20120101340A (ko) 2012-09-13
EP2473636B1 (en) 2016-10-26
AU2010289383B2 (en) 2015-04-16
BR112012004781A2 (pt) 2017-02-14
RU2012112802A (ru) 2013-10-10
CA2772921A1 (en) 2011-03-10
AU2010289383A1 (en) 2012-04-19
CY1118566T1 (el) 2017-07-12
HUE032917T2 (hu) 2017-11-28
EP2473636A4 (en) 2013-02-27
SMT201700063B (it) 2017-03-08
LT2473636T (lt) 2017-02-10
US20160024205A1 (en) 2016-01-28
ES2613055T3 (es) 2017-05-22
JP2013503642A (ja) 2013-02-04
JP5727484B2 (ja) 2015-06-03
SMT201700063T1 (it) 2017-03-08
ME02599B (me) 2017-06-20

Similar Documents

Publication Publication Date Title
DK2473636T3 (da) Type 1-interferondiagnostik
JP5411129B2 (ja) インターフェロンα誘導性薬力学的マーカー
KR101532797B1 (ko) 인터페론 알파 유도성 약력학적 마커
EP2252703B1 (en) Disease markers and uses thereof
AU2016295347A1 (en) Gene signature for immune therapies in cancer
KR20150090246A (ko) 암을 위한 분자 진단 테스트
KR20140044341A (ko) 암에 대한 분자적 진단 검사
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
JP2013526845A (ja) サイトカイン標的薬（ＣｙＴＤ）に対する、炎症性疾患に罹患している対象の初期応答または非応答を予測する遺伝子および遺伝子の組み合わせ
US20100261172A1 (en) Interferon alpha-induced pharmacodynamic markers
US20110046202A1 (en) Method for testing a subject thought to have or to be predisposed to asthma
WO2009155559A1 (en) Interferon alpha-induced pharmacodynamic markers
NZ618191B2 (en) Molecular diagnostic test for cancer
HK40037011A (en) Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
HK1140406A (en) Interferon alpha-induced pharmacodynamic markers
AU2014200127A1 (en) Interferon alpha-induced pharmacodynamic markers
HK1150063B (en) Disease markers and uses thereof